Telik, Inc. - Common Stock

Role of enzyme GSTP1-1 in progression of cancer, other diseases associated with increased cell proliferation
Date: Tue, 13 Jul 2010 13:48:48 GMT
Tags:

---

Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Date: Mon, 12 Jul 2010 18:27:28 GMT
Tags:

---

Telik, Inc. (TELK) Corporate Event Announcement Notice
Date: Sat, 10 Jul 2010 01:24:46 GMT
Tags:

---

Watch for Telik to Rebound after Falling 0.14% Yesterday (TELK)
Date: Fri, 09 Jul 2010 07:15:43 GMT
Tags:

---

MAY v. TELIK, INC.
Date: Tue, 22 Jun 2010 12:52:23 GMT
Tags:

---

TELIK INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfe (EDGAR Online)
Date: Thu, 29 Jul 2010 20:55:17 GMT
Tags:

---

Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments (PR Newswire)
Date: Mon, 12 Jul 2010 18:25:00 GMT
Tags:

Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html.  This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.  Telintra®, Telik's investigational drug candidate inhibitor of GSTP1-1, has recently been reported to show positive results in a Phase 2 trial in patients with MDS, a disease characterized by disordered cell proliferation and differentiation.  Reprints of the publication are available from Telik.  

---

Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl) (PR Newswire)
Date: Mon, 21 Jun 2010 18:33:00 GMT
Tags:

Telik, Inc. today announced the publication of a case report by Quddus et al., Oral Ezatiostat HCl and Myelodysplastic Syndrome: A case report of sustained hematologic response following an abbreviated exposure.

---

Telik Announces Positive Phase 2 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Patients with Myelodysplastic Syndrome (PR Newswire)
Date: Tue, 08 Jun 2010 13:00:00 GMT
Tags:

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of ezatiostat hydrochloride tablets in patients with an International Prognostic System Score low to intermediate-1 risk myelodysplastic syndrome .

---

Telik Announces Presentations and Webcasts at Investment Conferences (PR Newswire)
Date: Wed, 02 Jun 2010 20:05:00 GMT
Tags:

Telik, Inc. today announced that company management will provide corporate overviews at the following investment conferences:

---